Temsirolimus in advanced leiomyosarcomas: Patterns of response and correlation with the activation of the mammalian target of rapamycin pathway

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 463-467

  Italiano, Antoine ^a   Kind, Michèle ^a   Stoeckle, Eberhard ^a   Jones, Natalie ^a   Coindre, Jean Michel ^a   Bui, Binh ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Leiomyosarcoma; mammalian target of rapamycin; PTEN; sarcoma; temsirolimus

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; TEMSIROLIMUS; TRABECTEDIN;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE METASTASIS; CLINICAL ARTICLE; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCIDEMIA; LEIOMYOSARCOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; MEDICAL RECORD; MUCINOSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 79955068897     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283442074     Document Type: Article

References (24)

1. Enzinger M, Weiss SW. Enzinger and Weiss's soft tissue tumors. 5th ed. Mosby: Elsevier; 2008.
2. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007; 8:513-524. (Pubitemid 46823060)
3. El-Rifai W, Sarlomo-Rikala M, Knuutila S, Miettinen M. DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. Am J Pathol 1998; 153:985-990. (Pubitemid 28419051)
4. Otañ o-Joos M, Mechtersheimer G, Ohl S, Wilgenbus KK, Scheurlen W, Lehnert T, et al. Detection of chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics. Cytogenet Cell Genet 2000; 90:86-92.
5. Mandahl N, Fletcher CD, Dal Cin P, De Wever I, Mertens F, Mitelman F, et al. Comparative cytogenetic study of spindle cell and pleiomorphic leiomyosarcomas of soft tissues: a report from the CHAMP study group. Cancer Genet Cytogenet 2000; 116:66-73.
6. Derré J, Lagacé R, Nicolas A, Mairal A, Chibon F, Coindre JM, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001; 81:211-215. (Pubitemid 32176385)
7. Hu J, Rao UN, Jasani S, Khanna V, Yaw K, Surti U. Loss of DNA copy number of 10q is associated with aggressive behavior of leiomyosarcomas: a comparative genomic hybridization study. Cancer Genet Cytogenet 2005; 161:20-27. (Pubitemid 41096047)
8. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, et al. Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res 2006; 66:8984-8993. (Pubitemid 44521116)
9. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13:748-753. (Pubitemid 46889749)
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
11. Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
12. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33:37-42. (Pubitemid 14223231)
13. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759. (Pubitemid 46797957)
14. Gibault L. Recurrent genomic alterations in sarcomas with complex genomics: PTEN and DKK1 loss of expression, mechanisms and biological consequences. PhD thesis. University Paris Descartes, Paris, 2010. Print.
15. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008; 21:231-237. (Pubitemid 351304283)
16. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-644.
17. Chawla SP, Tolcher AW, Staddon AP, Schuetze S, D'Amato GZ, Blay JY, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial. J Clin Oncol (Meeting Abstracts) 2007; 25:10076.
18. Okuno SH, Mahoney MR, Bailey HH, Adkins DR, Maples WJ, Ettinger D, et al. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). J Clin Oncol (Meeting Abstracts) 2006; 24:9504.
19. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102:803-809.
20. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, et al. High-grade soft-tissue sarcomas: tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009; 251:447-456.
21. Pallares J, Bussaglia E, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005; 18:719-727. (Pubitemid 40676385)
22. Italiano A, Delcambre C, Hostein I, Cazeau AL, Marty M, Avril A, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010; 21:1135-1137.
23. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. Nat Genet 2010; 42:715-721.
24. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-1940. (Pubitemid 46474636)